Get started
Author

Alexandra J. McCraw

Observed names: Alex J McCraw, Alexa McCraw, Alexandra J McCraw, Alexandra McCraw
ORCID: 0009-0008-2412-4389
Observed ORCID: 0009-0008-2412-4389
OpenAlex ID: A5062848369
Combined anti‐PD‐1 and anti‐CTLA‐4 checkpoint blockade: Treatment of melanoma and immune mechanisms of action
2021 · Zena N. Willsmore, Ben G. T. Coumbe, et al. · European Journal of Immunology · 222
PDF
B Cells in Patients With Melanoma: Implications for Treatment With Checkpoint Inhibitor Antibodies
2021 · Zena N. Willsmore, Robert J. Harris, et al. · Frontiers in Immunology · 81
PDF
I g E glycosylation and impact on structure and function: A systematic review
2024 · Alexandra J. McCraw, Lais C. G. F. Palhares, et al. · Allergy · 14
AllergoOncology : Biomarkers and refined classification for research in the allergy and glioma nexus—A joint EAACI‐EANO position paper
2024 · Michelle C. Turner, Urszula Radzikowska, et al. · Allergy · 14
PDF
An Fc-Engineered Glycomodified Antibody Supports Proinflammatory Activation of Immune Effector Cells and Restricts Progression of Breast Cancer
2025 · Alicia M. Chenoweth, Anthony Cheung, et al. · Cancer Research · 7
Non‐Allergic Urticarial Skin Reactions Associated With MOv18 IgE , a First‐In‐Class IgE Antibody Recognising Folate Receptor Alpha
2025 · Chara Stavraka, Jitesh Chauhan, et al. · Allergy · 7
Fc-mediated immune stimulating, pro-inflammatory and antitumor effects of anti-HER2 IgE against HER2-expressing and trastuzumab-resistant tumors
2025 · Melanie Grandits, Lais C G F Palhares, et al. · Journal for ImmunoTherapy of Cancer · 7
PDF
Tuning antibody stability and function by rational designs of framework mutations
2025 · Joseph C. F. Ng, Alicia Chenoweth, et al. · mAbs · 5
Physiochemical and functional evaluation of the first-in-class anti-cancer IgE antibody drug, MOv18, through process development and good manufacturing practice production
2025 · Heather J Bax, Jitesh Chauhan, et al. · mAbs · 4
Phenotypic, functional, prognostic and predictive significance of B-cell and antibody responses in human melanoma: a scoping review
2026 · Lucy Booth, Xinyi Chen, et al. · British Journal of Dermatology · 2
AllergoOncology in Review: Harnessing Allergy in the Field of Oncology to Improve Patient Outcomes
2026 · Jakub Zydron, Anishaa Balaji, et al. · Clinical & Experimental Allergy · 2
PDF
An antibody-drug conjugate designed through clone and isotype selection restricts the growth of CSPG4-expressing triple-negative breast cancer
2026 · Benjamina Esapa, Yi Liu, et al. · npj Precision Oncology · 1
CD4 + T Cell‐Intrinsic Arg1 Regulates Th1 Dynamics in Influenza: Functional and Translational Implications for Infection and Cancer Inflammation
2026 · Anishaa Balaji, Sophia N. Karagiannis, et al. · Allergy
PDF
Data from An Fc-Engineered Glycomodified Antibody Supports Proinflammatory Activation of Immune Effector Cells and Restricts Progression of Breast Cancer
2025 · Alicia M. Chenoweth, Anthony Cheung, et al.
Figure 7 from An Fc-Engineered Glycomodified Antibody Supports Proinflammatory Activation of Immune Effector Cells and Restricts Progression of Breast Cancer
2025 · Alicia M. Chenoweth, Anthony Cheung, et al.
Supplementary Table 2 from An Fc-Engineered Glycomodified Antibody Supports Proinflammatory Activation of Immune Effector Cells and Restricts Progression of Breast Cancer
2025 · Alicia M. Chenoweth, Anthony Cheung, et al.
Supplementary Figure 2 from An Fc-Engineered Glycomodified Antibody Supports Proinflammatory Activation of Immune Effector Cells and Restricts Progression of Breast Cancer
2025 · Alicia M. Chenoweth, Anthony Cheung, et al.
Figure 3 from An Fc-Engineered Glycomodified Antibody Supports Proinflammatory Activation of Immune Effector Cells and Restricts Progression of Breast Cancer
2025 · Alicia M. Chenoweth, Anthony Cheung, et al.
Figure 2 from An Fc-Engineered Glycomodified Antibody Supports Proinflammatory Activation of Immune Effector Cells and Restricts Progression of Breast Cancer
2025 · Alicia M. Chenoweth, Anthony Cheung, et al.
Figure 5 from An Fc-Engineered Glycomodified Antibody Supports Proinflammatory Activation of Immune Effector Cells and Restricts Progression of Breast Cancer
2025 · Alicia M. Chenoweth, Anthony Cheung, et al.
Supplementary Figure 1 from An Fc-Engineered Glycomodified Antibody Supports Proinflammatory Activation of Immune Effector Cells and Restricts Progression of Breast Cancer
2025 · Alicia M. Chenoweth, Anthony Cheung, et al.
Figure 8 from An Fc-Engineered Glycomodified Antibody Supports Proinflammatory Activation of Immune Effector Cells and Restricts Progression of Breast Cancer
2025 · Alicia M. Chenoweth, Anthony Cheung, et al.
Figure 4 from An Fc-Engineered Glycomodified Antibody Supports Proinflammatory Activation of Immune Effector Cells and Restricts Progression of Breast Cancer
2025 · Alicia M. Chenoweth, Anthony Cheung, et al.
Figure 6 from An Fc-Engineered Glycomodified Antibody Supports Proinflammatory Activation of Immune Effector Cells and Restricts Progression of Breast Cancer
2025 · Alicia M. Chenoweth, Anthony Cheung, et al.
Supplementary Figure 5 from An Fc-Engineered Glycomodified Antibody Supports Proinflammatory Activation of Immune Effector Cells and Restricts Progression of Breast Cancer
2025 · Alicia M. Chenoweth, Anthony Cheung, et al.
Works count: 33
Citation count: 366
H-index: 7
I10-index: 4
Year
Topic
Type